| scholarly article | Q13442814 |
| P50 | author | David Schaffer | Q59749936 |
| P2093 | author name string | James T Koerber | |
| Jae-Hyung Jang | |||
| P2860 | cites work | Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. | Q35111738 |
| Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes | Q35139648 | ||
| Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. | Q35140088 | ||
| Gene therapy: twenty-first century medicine | Q36161193 | ||
| Optimization of DNA shuffling for high fidelity recombination | Q36852677 | ||
| Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids | Q38299901 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production | Q39698557 | ||
| Characterization of tissue tropism determinants of adeno-associated virus type 1. | Q39700318 | ||
| Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding | Q39756934 | ||
| Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency | Q40088147 | ||
| Nucleotide sequence and organization of the adeno-associated virus 2 genome | Q40143539 | ||
| Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells | Q40551839 | ||
| Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization | Q42203239 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly | Q42424876 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q42609041 | ||
| Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors | Q43740107 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q45745995 | ||
| Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector | Q45769447 | ||
| Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
| Structure-guided recombination creates an artificial family of cytochromes P450. | Q21146061 | ||
| Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism | Q24515072 | ||
| Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity | Q24529161 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups | Q24623923 | ||
| Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 | ||
| Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector | Q27647639 | ||
| Rapid evolution of a protein in vitro by DNA shuffling | Q28245873 | ||
| Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo | Q28572747 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies | Q30841593 | ||
| Molecular breeding of viruses | Q30898162 | ||
| Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection | Q30923081 | ||
| Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity | Q30923970 | ||
| Protein building blocks preserved by recombination | Q31065876 | ||
| Molecular evolution by staggered extension process (StEP) in vitro recombination | Q32075357 | ||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors | Q33232270 | ||
| Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. | Q33248235 | ||
| High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells | Q33255756 | ||
| Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography | Q33282204 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
| Cloning and characterization of adeno-associated virus type 5. | Q33641228 | ||
| The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity | Q34124491 | ||
| Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties | Q34228552 | ||
| Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
| Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6 | Q35024289 | ||
| Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. | Q35025591 | ||
| The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9 | Q35101411 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1703-1709 | |
| P577 | publication date | 2008-08-26 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | DNA shuffling of adeno-associated virus yields functionally diverse viral progeny | |
| P478 | volume | 16 |
| Q40532321 | A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons |
| Q36006011 | A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. |
| Q45878143 | A calcium-sensitive promoter construct for gene therapy |
| Q21142728 | A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells |
| Q36715338 | A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype |
| Q35695082 | AAV ancestral reconstruction library enables selection of broadly infectious viral variants. |
| Q33659389 | AAV's anatomy: roadmap for optimizing vectors for translational success |
| Q49894243 | AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement |
| Q38856794 | Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. |
| Q64041060 | Adeno-associated Virus (AAV) versus Immune Response |
| Q35095825 | Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala |
| Q38706321 | Adeno-associated virus (AAV) vectors in cancer gene therapy. |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q38190041 | Adeno-associated virus vectors and neurological gene therapy |
| Q34332817 | Adeno-associated virus: fit to serve |
| Q38199047 | Advances in AAV vector development for gene therapy in the retina |
| Q33790771 | An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells |
| Q39076892 | Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates |
| Q34572922 | Atomic modeling of cryo-electron microscopy reconstructions--joint refinement of model and imaging parameters |
| Q37066323 | Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. |
| Q37277305 | CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes |
| Q38348602 | CRISPR genome engineering and viral gene delivery: a case of mutual attraction |
| Q36427105 | Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. |
| Q64926507 | Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting. |
| Q34080512 | Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells |
| Q33484220 | Directed evolution of adeno-associated virus for glioma cell transduction |
| Q24649385 | Directed evolution of adeno-associated virus to an infectious respiratory virus |
| Q34188892 | Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. |
| Q39331772 | Distinct transduction difference between adeno-associated virus type 1 and type 6 vectors in human polarized airway epithelia |
| Q28083324 | E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution |
| Q35651062 | Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho(-/-) mouse |
| Q41815391 | Engineered AAV vectors for improved central nervous system gene delivery |
| Q52333355 | Engineered viral vectors for functional interrogation, deconvolution, and manipulation of neural circuits. |
| Q37075772 | Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors |
| Q38212776 | Engineering adeno-associated viruses for clinical gene therapy |
| Q34227421 | Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. |
| Q35635046 | Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant |
| Q35192893 | Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus |
| Q89841932 | Enhancer-Driven Gene Expression (EDGE) Enables the Generation of Viral Vectors Specific to Neuronal Subtypes |
| Q34069571 | Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity |
| Q35340196 | Gene therapy for the nervous system: challenges and new strategies |
| Q37856565 | Genetic therapy for the nervous system |
| Q33555864 | Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q35450610 | Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering. |
| Q35952312 | In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector |
| Q42739394 | Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes |
| Q41921977 | In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ. |
| Q88166600 | Liver induced transgene tolerance with AAV vectors |
| Q38187651 | Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors |
| Q35799937 | MiRNA inhibition in tissue engineering and regenerative medicine |
| Q33492733 | Molecular evolution of adeno-associated virus for enhanced glial gene delivery |
| Q40100060 | Next-generation AAV vectors for clinical use: an ever-accelerating race |
| Q61813605 | Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses |
| Q45871641 | Novel GP64 envelope variants for improved delivery to human airway epithelial cells. |
| Q30899756 | Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes |
| Q40097321 | Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer |
| Q33995646 | Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo |
| Q36406869 | Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy |
| Q34633598 | Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector |
| Q35971198 | Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries |
| Q36983193 | Recent advances in RNA interference therapeutics for CNS diseases |
| Q95327465 | Recent development of AAV-based gene therapies for inner ear disorders |
| Q54206545 | Recent progress and considerations for AAV gene therapies targeting the central nervous system. |
| Q91707074 | Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? |
| Q27008438 | Recombination in eukaryotic single stranded DNA viruses |
| Q39884792 | Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors |
| Q40097476 | Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells |
| Q37676218 | Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure |
| Q21245112 | Selective gene silencing by viral delivery of short hairpin RNA |
| Q33526697 | Sites in the AAV5 capsid tolerant to deletions and tandem duplications |
| Q96816750 | Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties |
| Q30152836 | Structure of neurotropic adeno-associated virus AAVrh.8. |
| Q34487264 | Synthetic virology: engineering viruses for gene delivery |
| Q64241403 | Targeted Gene Delivery into the Mammalian Inner Ear Using Synthetic Serotypes of Adeno-Associated Virus Vectors |
| Q37878086 | Targeted gene therapy for the treatment of heart failure |
| Q33633258 | The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide. |
Search more.